Explore
Validate
LearnALX-210-744-C200
antibody from Enzo Life Sciences
Targeting: TNFRSF10C
CD263, DcR1, LIT, TRAILR3, TRID
Western blot
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-210-744-C200 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-210-744-C200, RRID:AB_2052730
- Product name
- TRAIL-R3 (human) polyclonal antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Epitope-affinity purified IgG.
- Reactivity
- Human
- Host
- Goat
- Vial size
- 200 μg
- Storage
- -20°C
- Handling
- For maximum product recovery after thawing, centrifuge the vial before opening the cap. Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20¡C.
Submitted references High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas.
Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain.
The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein.
Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1.
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Omer A, Griffith TS, Sanlioglu S
Pancreas 2008 May;36(4):385-93
Pancreas 2008 May;36(4):385-93
Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain.
Dörr J, Bechmann I, Waiczies S, Aktas O, Walczak H, Krammer PH, Nitsch R, Zipp F
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002 Feb 15;22(4):RC209
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002 Feb 15;22(4):RC209
The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein.
Basile JR, Zacny V, Münger K
The Journal of biological chemistry 2001 Jun 22;276(25):22522-8
The Journal of biological chemistry 2001 Jun 22;276(25):22522-8
Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1.
Bernard D, Quatannens B, Vandenbunder B, Abbadie C
The Journal of biological chemistry 2001 Jul 20;276(29):27322-8
The Journal of biological chemistry 2001 Jul 20;276(29):27322-8
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Déjosez M, Ramp U, Mahotka C, Krieg A, Walczak H, Gabbert HE, Gerharz CD
Cell death and differentiation 2000 Nov;7(11):1127-36
Cell death and differentiation 2000 Nov;7(11):1127-36
No comments: Submit comment
Supportive validation
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Specificity of PAb to TRAIL-R3. Lane 1: TRAIL-R3:Fc. Lane 2: TRAIL-R2. ALX-210-744 recognizes an approx. 66kDa band of the expected size of the recombinant TRAIL-R3:Fc protein in lane 1 and shows no detectable cross-reactivity to TRAIL-R2:Fc in lane 2.
